Punto Health
Category: AI in Healthcare
AI-powered cognitive care platform combining speech-based digital biomarkers with personalized daily support and clinician dashboards for dementia and cognitive decline. Punto Health was founded in 2023. The company is led by Anna Muñoz Farré. Based in London, United Kingdom. Team size: 11-50. Total funding raised: $3.5M. Latest round: Seed. Key investors include Shilling VC, Plus Partners, Exceptional Ventures, HEARTFELT_, Fondo Bolsa Social, Abac Nest Ventures, Deuce Capital, Lavender Ventures.
- Founded
- 2023
- Headquarters
- London, United Kingdom
- Team size
- 11-50
- Total funding
- $3.5M
Value proposition
Shifts dementia and cognitive care from reactive to proactive by enabling earlier detection (via speech-based digital biomarkers) and continuous, personalized day-to-day support connecting patients, carers, and clinicians.
Products and solutions
PuntoTest (5-min speech-based digital biomarker for cognitive assessment/early detection), PuntoCare (personalized daily care app for patients and carers with cognitive stimulation, mood tracking, education), PuntoClinic (clinician dashboard for remote monitoring and care coordination).
Unique value
Only full-stack 'OS for dementia care' combining clinically-validated speech AI biomarkers with a continuous patient/carer support ecosystem and clinician-facing dashboard, validated with multiple NHS trusts and Spanish hospital systems.
Target customer
Healthcare providers (NHS trusts, memory clinics, hospitals), home care organizations, and individual patients/carers/active seniors experiencing or at risk of cognitive decline.
Industries served
Healthcare, Digital Health, Elderly/Senior Care, Neurology
Technology advantage
Speech-based AI digital biomarker model trained on clinical cohorts (SMC, MCI, dementia); NHS DTAC compliant, GDPR compliant, UKCA/CE pathway; extensive real-world clinical validation data (100k+ exercises, 2,000+ cognitive tests, 800+ users).
How they differentiate
Full-stack platform spanning assessment (PuntoTest), continuous care (PuntoCare), and clinical dashboard (PuntoClinic) rather than a point solution; deep co-design and validation with NHS and Spanish clinical partners rather than pure consumer app.
Main competitors
Linus Health, Neurotrack, Novoic, Cognetivity Neurosciences, Winterlight Labs
Key partnerships
Ace Alzheimer Center Barcelona, North London NHS Foundation Trust, Oxleas NHS Foundation Trust, Hospital General de Granollers, Hospital del Mar, Consorci Sanitari de l'Alt Penedès, NIHR-funded NHS studies, UCLPartners.
Notable customers
Ace Alzheimer Center Barcelona, North London NHS Foundation Trust, Oxleas NHS Foundation Trust, Hospital General de Granollers, Hospital del Mar, AgeUK Enfield
Major milestones
2025: NN Group Social Innovation Startup Award + €100K grant, co-designed platform validated across NHS memory services and Spanish hospitals reaching 2,000+ people, Dec 2025: $2.7M/€2.3M seed round closed, 2026: won BCG X Social Impact Accelerator, presentations at 36th Alzheimer Europe Conference (2026) and 21st EuGMS Congress (2025).
Growth metrics
800+ active users; 100k+ cognitive stimulation exercises completed; 2,000+ cognitive tests performed; 71.3% adherence after 1 month; 50% retention at 6 months (per Granollers General Hospital neurology study, N=107).
Market positioning
Early-stage clinically-validated digital health platform positioned as connective tissue between speech-AI diagnostics and everyday dementia/cognitive care management, targeting both healthcare systems (NHS) and direct patient/carer use.
Geographic focus
UK and Spain initially, with NHS system focus; global cognitive-care AI market includes US-based competitors (Linus Health, Neurotrack).
About Anna Muñoz Farré
Ex-Senior AI Scientist at BenevolentAI; Ex-Data Scientist at Elvie; research experience at MIT and UPC-Barcelona Tech; publications at NeurIPS and ICML.
Latest news about Punto Health
More AI in Healthcare companies
Official website: https://puntohealth.com